The ready-to-use lentiviral particles of Lenti-OVA TCR-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Human TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.
Type of Therapeutics
T cell receptor
This peptide is amino acids 323 to 339 amidated fragment of ovalbumin (OVA), the H-2b-restricted
OVA class II epitope. This peptide is recognized by many T cells because it contains multiple T cell
epitopes. This OVA fragment contains a nested set of CD4+ T cell epitopes. OVA 323 to 339 can be
presented by I-Ad in at least three binding registers. The residues 327 to 333 are critical for peptide
binding to I-Ad
Tra-P1A; Trap1a; tumor rejection antigen P1A; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; Spleen cancer; thymus cancer; liver cancer; lung cancer
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.